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The use of tunneled semipermanent intraperitoneal catheters is becoming increasingly widespread in the management of intractable malignant ascites.
There is a lack of published data on the successful management of complications of these catheters in cases of malignant ascites. The current study reports
four cases of nonfunctioning catheters due to ﬁbrin blockage or ascitic loculation, all of which were successfully treated with intraperitoneal ﬁbrinolysis
with streptokinase.
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Malignant ascites is a common condition in patients exhibiting
an intraperitoneal tumor spread. It is a frequent cause of morbidity,
causing intractable nausea, anorexia, dyspnea, and painful
abdominal distension, all of which markedly reduce a patient’s
quality of life. Traditionally this has required repeated inpatient
admissions with temporary intraperitoneal catheter placement.
Tunneled semipermanent intraperitoneal catheters have now
gained acceptance as the primary method for long-term para-
centesis, allowing out of hospital management. Literature reviews
have demonstrated it to be a safe and effective technique with a
similar or lower complication proﬁle to standard large volume
nontunneled paracentesis. Tunneled catheter malfunction due to
ﬁbrin formation, ascitic loculation, and peritonitis appear uncom-
mon in the setting of malignant ascites.1 In a large, single-center
study, 170 patients had tunneled intraperitoneal catheter place-
ment for malignant ascites. The dwell time ranged between 0 and
796 days (mean 60 days) with ﬁve occlusions/tube malfunctions.2
Tube malfunction is a well-recognized complication in similarly
designed long-term tunneled catheters inserted for continuous
ambulatory peritoneal dialysis (CAPD), eventually occurring in up
to 65% of cases, and has recognized management strategies.3 No
standardized protocol exists for the management of catheter mal-
function in respect to malignant ascites and long-term tunneled
catheters. This study reports the experience of four cases of cath-
eter blockage and ascitic loculation, successfully treated with
intraperitoneal streptokinase administered via 15.5F tunneled1 The University of Shefﬁeld, The Medical School, Beech Hill Rd, Shefﬁeld, South Yorkshire S1
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and suggests a management strategy for malfunctioning catheters.
Case reports
Case 1
A 34-year-old male with Stage IV gastric adenocarcinoma and
recurrent malignant ascites presented with a nonfunctioning
tunneled catheter 9 weeks post insertion. Initial ultrasound
showed a large volume densely loculated ascites (Fig. 1A). A tubo-
gram showed a patent catheter lumen with reduced dispersal
beyond the side holes in keeping with the ascitic loculation. In an
attempt to salvage the catheter without requiring removal, ﬁbri-
nolysis with 250,000 IU of streptokinase was delivered once daily
for a total of 5 days via the tunneled catheter. Follow-up ultrasound
on Day 2 showed a reduction in ascites with a functioning catheter
permitting drainage of ascites. Sequential daily ultrasounds
demonstrated almost complete resolution of the loculated ascites
by Day 5 (Fig. 1B). No adverse events were reported following
intraperitoneal ﬁbrinolysis and the patient had successful palliation
of ascites at home until death 3 weeks later.
Case 2
A 59-year-old male with Stage IV renal cell carcinoma presented
with a nonfunctioning catheter 10weeks post insertion. Ultrasound
showed a large volume of loculated ascites, and a tubogram0 2RX, UK
ton, Manchester, M20 4BX, UK.
vier. Open access under CC BY-NC-ND license.
Fig. 1. (A) Longitudinal ultrasound scan through the right upper quadrant demon-
strating dense loculated ascites with a honeycomb appearance (white arrow) and
inferior liver (black arrow). (B) Longitudinal scan of the right upper quadrant on Day 5
on ﬁbrinolysis showing liver (black arrow) and minimal residual ascites (white arrow).
Fig. 2. (A) Tubogram showing an occluded distal lumen. A stiff 0.035 inch guidewire
has buckled within a ﬁbrin plug during attempted recanalisation (black arrow). Poor
dispersal of contrast beyond the catheter side holes (white arrow) is in keeping with
loculation. (B) Removal of the PleurX catheter shows a ﬁbrin plug occluding the lumen
(black arrow). (C) Post ﬁbrinolysis tubogram shows a mobile catheter with free
dispersal of contrast amongst bowel loops (black arrow) in keeping with the disso-
lution of loculation.
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contrast beyond the fenestrated side holes suggesting catheter
occlusion (Fig. 2A). An attempt to recanalize the catheter with a stiff
0.035 inch guide wire was unsuccessful, and it was felt that intra-
peritoneal ﬁbrinolysis might not be deliverable through the
occluded catheter lumen. This prompted catheter removal, con-
ﬁrming a ﬁbrin plug causing the occlusion (Fig. 2B). A new tunneled
catheter was inserted allowing ﬁbrinolysis to be delivered once
daily for 5 days. Follow-up ultrasound studies showed decreasing
loculation with successive daily ﬁbrinolysis. A tubogram on Day 5
showed free dispersal of contrast between bowel loops in the
pelvis. The catheter had spontaneously repositioned in the lower
abdomen (Fig. 2C) suggesting dissolution of the loculation. Free
drainage of ascites to resolution, was conﬁrmed with same-day
ultrasound. The patient had uneventful and successful drainage of
ascites at home, until death 7 weeks later.Fig. 3. (A) Transverse ultrasound image of the pelvis showing a honeycomb appear-
ance (white arrow) indicating densely loculated ascites. (B) Transverse ultrasound
image of the pelvis on the second day of ﬁbrinolysis showing markedly reduced
loculation with some residual ﬁbrin stranding in the midline (white arrow).Case 3
A 55-year-old female with Stage IV breast carcinoma presented
with a nonfunctioning tunneled catheter 11 weeks post insertion.
An ultrasound study demonstrated densely loculated ascites
throughout the abdomen and pelvis (Fig. 3A). A same-day
computed tomography (CT) scan underestimated the extent of as-
citic loculation but showed no evidence of catheter kink, migration,
or misplacement. A subsequent tubogram demonstrated an
obvious catheter lumenwith poor dispersal around the catheter tip,
again in keeping with ascitic loculation. As the lumen was evident
on the tubogram study, the catheter was not removed on this
occasion and ﬁbrinolysis was delivered once daily for 5 days. An
ultrasound performed on Day 2 of ﬁbrinolytic therapy showed
markedly reduced loculation with a clinically functioning catheter
(Fig. 3B). Ultrasound examination on Day 5 of therapy demon-
strated further radiological improvement with complete resolution
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of ascites at home until death 13 months later.Case 4
A 68-year-old femalewith a Stage IV neuroendocrine carcinoma,
peritoneal metastasis, and recurrent malignant ascites presented
with a nonfunctioning tunneled catheter 24 weeks following
placement. Initial ultrasound showed a large volume of non-
loculated ascites (Fig 4A). It proved impossible to aspirate the as-
cites and attempts to ﬂush the tube were also unsuccessful. CT was
performed to exclude tube migration into a dry area of the peri-
toneum and demonstrated a well-placed tube lying in the body of
ascites (Fig. 4B) A tubogram demonstrated poor dispersal of
contrast beyond the catheter side holes, and attempted 0.0035 inch
guide-wire recanalization of the catheter was not possible, further
suggesting ﬁbrin plug occlusion (Fig. 4C). The catheter was left in
situ on this occasion, and ﬁbrinolysis was delivered into the
indwelling catheter, resulting in free drainage and ascetic resolu-
tion by Day 3 of treatment. The patient achieved successful
drainage of ascites at home until death 38 weeks post ﬁbrinolysis.
Discussion
These cases report the successful use of intraperitoneal ﬁbri-
nolytics in the treatment of occluded tunneled catheters and
loculated malignant ascites. No standardized protocols exist for
the investigation or management of nonfunctioning tunneled
catheters in this setting. While there are no large scale studies to
accurately describe the safety proﬁle of ﬁbrinolytic drugs in the
treatment of complicated malignant ascites, intraperitoneal ﬁbri-
nolysis is, however, a recognized therapy in cases of ﬁbrinous
occlusion, ﬂuid loculation, and peritonitis in CAPD catheter
dysfunction.2,4 In addition, it is a recommended therapy for
symptomatic, loculated malignant pleural effusions, and empy-
ema.4 There is no evidence of any increased relative risk of allergic
reaction, or local/systemic hemorrhagic complication with the use
of intraperitoneal ﬁbrinolysis in CAPD catheter malfunction, orFig. 4. (A) Longitudinal ultrasound scan of the upper abdomen showing uncomplicated asc
catheter (white arrow) lies within the sump of the ﬂuid and not between the omentum. (C
with a guide-wire inserted into the catheter (black arrow) unable to advance suggesting luwith intrapleural administration, even when the pleural effusion
is hemorrhagic in origin.5–8
The lack of literature regarding the management of similar
complications in tunneled catheters with malignant ascites may be
a reﬂection of reduced long-term in situ catheter exposure in
oncology patients with ascites who have a mean life expectancy of
1–4 months.9 However, as the use of tunneled intraperitoneal
catheters increases, it is expected that they will become an earlier
intervention in the management of ascites. Thus, long-term com-
plications may become more prevalent. Of note, the patients
described presented with complications at 9, 10, 11, and 24 weeks
following tunneled catheter insertion, which is at or beyond the
upper limit of expected mean survival following development of
ascites.9
As no large scale studies currently exist, the use of intraperito-
neal ﬁbrinolytics should be assessed on a risk verses beneﬁt sce-
nario for each individual patient. Investigation should consider
combined multimodality imaging prior to any potential ﬁbrinolytic
therapy to exclude a nonﬁbrinous occlusion. If ultrasound conﬁrms
the presence of complicated ascites and loculation, CT can exclude
catheter kink, misplacement, or migration into the lesser sac or
omental layers, which might not be detectable by ﬂuoroscopy or
ultrasound alone. Of note however, CT underestimates the true
extent of loculation (the ascitic ﬂuid appearing uncomplicated on
CT in all of the above described cases). A tubogram can then be
performed to assess lumen patency, and determine whether
thrombolytic agents can be delivered via the indwelling catheter. If
the lumen appears completely blocked, new intraperitoneal access
can be considered, but a bolus of ﬁbrinolytic therapy into the
catheter lumen may prove successful.
Based on previous publications detailing the ﬁbrinolytic man-
agement of malignant loculated pleural effusions and CAPD related
peritonitis,2,4,5,8 a dose of 250,000 IU of streptokinasewas dissolved
in 50 mL 0.9% saline and administered via the tunneled catheter
which was then clamped, ascitic drainage was subsequently per-
formed 24 hours following administration. Fibrinolysis was
repeated daily until there was radiological and clinical evidence of
locule resolution and/or a normally functioning catheter, which
occurred between 3 and 5 days in the described cases.ites overlying bowel loops. (B) Computed tomography scan conﬁrming that the distal
) Tubogram showing limited dispersal of contrast beyond the side holes (white arrow)
men occlusion.
Gastrointestinal Intervention 2015 4(1), 61–6464In conclusion, this study reports four cases of nonfunctioning
PleurX intraperitoneal catheters due to loculation and/or ﬁbrin
occlusion, which provoked slightly different management strate-
gies. In all cases, streptokinase administered via the indwelling
catheters achieved long-term secondary patency without compli-
cation. No hemorrhagic sequelae were encountered despite peri-
toneal dissemination of the tumor. It is a cost-effective and simple
therapy which suggests that it should be considered in any cases of
suspected ﬁbrin blockage or loculated ascites with respect to ma-
lignant ascites and tunneled catheters.
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